Insights

Clinical Value Proof Noscendo's DISQVER metagenomic platform enables rapid, precise pathogen identification without assumptions, addressing sepsis diagnosis and enabling targeted therapy; ongoing German trial and recent financing provide compelling use cases to approach hospitals with a value-driven procurement narrative.

Funding & Trials Recent financing and a major German trial signal validation and momentum to accelerate pilots and scale adoption; leverage these milestones to engage EU healthcare networks, reimbursement teams, and potential distribution partners.

Strategic Partnerships Past collaborations with University Hospital Bonn and SensID for contamination-free reference materials, plus a board appointment and Health-i Pioneer recognition, establish credibility and co-development pathways attractive to research hospitals and pharma partners.

Market Positioning As a compact, innovative player in infection diagnostics, Noscendo can partner with larger manufacturers for distribution and system integration, tapping hospital networks in NRW and beyond while expanding capabilities to cfDNA sequencing and resistance profiling.

Sales & Adoption Target hospital systems, academic medical centers, and reference labs with a staged use case focused on sepsis and infection management; emphasize reliability and patient outcomes, support with pilot projects, and align with regulatory and reimbursement processes to shorten sales cycles.

Noscendo Tech Stack

Noscendo uses 8 technology products and services including Gravatar, Open Graph, Twemoji, and more. Explore Noscendo's tech stack below.

  • Gravatar
    Audio, Video, Graphics
  • Open Graph
    Content Management System
  • Twemoji
    Font Scripts
  • Tippy.js
    Javascript Libraries
  • JavaScript
    Programming Languages
  • HSTS
    Security
  • Piwik
    System Analytics & Monitoring
  • HTML5
    Web Tools And Plugins

Noscendo's Email Address Formats

Noscendo uses at least 1 format(s):
Noscendo Email FormatsExamplePercentage
First.Last@noscendo.comJohn.Doe@noscendo.com
97%
Last.First@noscendo.comDoe.John@noscendo.com
3%

Frequently Asked Questions

What is Noscendo's official website and social media links?

Minus sign iconPlus sign icon
Noscendo's official website is noscendo.com and has social profiles on LinkedIn.

What is Noscendo's SIC code NAICS code?

Minus sign iconPlus sign icon
Noscendo's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Noscendo have currently?

Minus sign iconPlus sign icon
As of July 2026, Noscendo has approximately 36 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: A. K.Cto: P. S.Vp People: C. K. A. C.. Explore Noscendo's employee directory with LeadIQ.

What industry does Noscendo belong to?

Minus sign iconPlus sign icon
Noscendo operates in the Biotechnology Research industry.

What technology does Noscendo use?

Minus sign iconPlus sign icon
Noscendo's tech stack includes GravatarOpen GraphTwemojiTippy.jsJavaScriptHSTSPiwikHTML5.

What is Noscendo's email format?

Minus sign iconPlus sign icon
Noscendo's email format typically follows the pattern of First.Last@noscendo.com. Find more Noscendo email formats with LeadIQ.
Noscendo logo

Noscendo

Biotechnology ResearchNorth Rhine-Westphalia, Germany11-50 Employees

Noscendo is a biotechnology research company based in Duisburg, North Rhine-Westphalia, Germany. It focuses on infection diagnostics through its metagenomic technology, DISQVER, which aims to identify pathogens rapidly and without assumptions to help clinicians determine appropriate treatments in a timely manner. The company serves medical professionals and healthcare institutions seeking improved diagnostic accuracy for infectious diseases, with the goal of reducing unnecessary mortality from infections. Noscendo describes its work as advancing modern medicine by prioritizing patient outcomes and fostering a collaborative, reliable approach within its team.

Founded and operating in the biotechnology sector, Noscendo emphasizes openness and accountability in its culture, aiming to deliver results that matter for patient care. The company has a history of collaboration and development efforts, including partnerships and leadership additions, and positions itself within a broader ecosystem of diagnostic innovation in Europe. Recent activity indicates ongoing progress in validating its diagnostic capabilities in clinical contexts.” } I'm not allowed to include more than 2 paragraphs; this version keeps two concise paragraphs, neutral tone, and avoids promotional language. If you prefer a shorter version, I can condense further. } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } }

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Noscendo's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Noscendo's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.